US Market Pressure Weighs on Glenmark's Q3 Earnings, Profit Below Estimates
Glenmark reported a consolidated net profit of 3.48 billion rupees (USD 40.15 million) for the quarter ended December 31.
Written By : Farhat Nasim
Published On 2025-02-15 10:05 GMT | Update On 2025-02-15 10:05 GMT
Glenmark launches generic ophthalmic solution
Bengaluru: India's Glenmark Pharmaceuticals reported third-quarter profit below estimates on Friday due to bleak U.S. demand for its long-term illness drugs.
The drugmaker reported a consolidated net profit of 3.48 billion rupees ($40.15 million) for the quarter ended December 31, compared with analysts' estimate of 3.64 billion rupees, as per data compiled by LSEG.
The company reported a loss of 3.51 billion rupees in the comparable quarter last year, hurt by sluggish sales in India and charges related to a legal case settlement in the United States. Net sales rose 34per cent to 33.02 billion rupees in the quarter, aided by India sales.
The U.S. is a major revenue source for India's generic drugmakers, but intense competition in North America's drug market has pressured their margins. Analysts had flagged that Glenmark's growth in North America has been hampered by price erosion and lack of significant product launches. Revenue from its U.S. markets grew 1.4per cent during the quarter, compared with a 5.5per cent growth in the previous quarter.
However, the company said it anticipates business growth from the financial year 2026 onward, driven by potential launches in the respiratory and injectable segments.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.